404
Views
2
CrossRef citations to date
0
Altmetric
Research Articles

Synthesis, Molecular Modeling, and Anticancer Screening of Some New Imidazothiadiazole Analogs

Pages 5833-5854 | Received 05 May 2021, Accepted 12 Jul 2021, Published online: 29 Jul 2021
 

Abstract

A series of N-aryl-2-((6-arylimidazo[2,1-b]thiadiazol-2-yl)thio)acetamide compounds 4 and 5 was synthesized by heterocyclization of their precursors N-aryl-2-((5-amino-1,3,4-thiadiazol-2-yl)thio)acetamides 3a–c with phenacyl chloride reagents. The structural and spectral features of the synthesized compounds were studied using DFT calculations. The DFT-estimated 1H NMR spectral data exhibited good agreement with the experimental data. Furthermore, the HOMO–LUMO energies were used in determination of some chemical reactivity descriptors. The cytotoxic activities of the prepared imidazothiadiazoles were evaluated toward four different cancer cell lines. Derivatives 5c, 4c, 5a, and 4a presented powerful cytotoxic results against breast cancer rather than the residual derivatives 5b and 4b compared with 5-fluorouracil as a reference. Meantime, the docking study was used on the synthesized imidazothiadiazole analogs and furnished adequate results toward PDB ID: 1DLS.

Disclosure statement

The author declares that there is no conflict of interest regarding the publication of this paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.